Novartis | NVS - Pre Tax Profit


Novartis reported $5.17B in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bausch Health Companies USD 56M 162M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Canopy Growth CAD -62.26M 60.84M Dec/2025
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Drreddys Laboratories INR 15.43B 1.96B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Glaxosmithkline GBP 2.46B 569M Sep/2025
J&J USD 7.82B 2.86B Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novartis USD 5.17B 637M Sep/2025
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 61.81M 7.32M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sanofi EUR -1.16B 6.23B Dec/2025
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
Zoetis USD 761M 126M Dec/2025